^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients
Published date:
03/02/2022
Excerpt:
We performed a single-center retrospective study of sarcoma patients treated with trabectedin with long-term follow-up. In total, 147 sarcoma patients treated with trabectedin were analyzed, with a mean follow-up time of 5 years. At 5 years, increased PD-L1 expression corresponded to worse outcomes (HR = 1.87, p = 0.04, q = 0.199)...high PD-L1 expression were less likely to benefit from trabectedin...
DOI:
10.3390/cancers14051290
